Evidence map›Paper›PMID 40394580›Full record

ArticleJournal of translational medicine2025

Methodological considerations in assessing modifiable risk factors across cancer survivorship.

Yuhan Zhou, Fen Chen, Huantian Li, Wenzhi Wang, Peng An

Abstract readLetter
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuhan Zhou *Department of Oncology, Radiology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang , 441000, China.
Fen Chen *Department of Oncology, Radiology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang , 441000, China.
Huantian Li *Department of Oncology, Radiology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang , 441000, China.
Wenzhi WangDepartment of Oncology, Radiology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang , 441000, China. wangyxyyy@126.com.
Peng AnDepartment of Epidemiology, Reproductive Medicine, The Fourth Clinical Medical College, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Hubei, P.R.C, Xiangyang , 441000, China. drpengan@foxmail.com.

Funding

General Program of Hubei Provincial Natural Science Foundation of China 2025AFB885Innovative Research Program of Xiangyang No.1 People's Hospital XYY2025SD17the "323" Major Chronic Disease Project of the Hubei Provincial Health Commission and Xiangyang NO.1 People's Hospital XYY2022-323
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40394580
PMCPMC12090405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.